Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress - read this article along with other careers information, tips and advice on BioSpace
Germline genetic testing can benefit all cancer patients as a routine practice in cancer care New data to be presented at 2021 ASCO Annual Meeting highlight need for increased germline testing in all cancer patients regardless of medical policy
News provided by
Share this article
Share this article
SAN FRANCISCO, May 25, 2021 /PRNewswire/ Invitae Corporation (NYSE: NVTA), a leading medical genetics company, is presenting multiple studies in multiple cancer types at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting showing all cancer patients can benefit from germline genetic testing to guide their care. The use of genetic information informs changes in cancer care, increases access to precision therapies and guides screening for high-risk individuals and their family members. Earlier detection and precision therapies are critical to increase survivorship for people with cancer, yet the oncology community has been slow to adopt routine testing.
Exact Therapeutics Abstract on its Phase I ACTIVATE Study to be Presented at the 2021 ASCO Annual Meeting
News provided by
Share this article
Share this article
OSLO, Norway and LONDON, May 20, 2021 /PRNewswire/ Exact Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) to harness the power of ultrasound in therapeutic amplification across multiple therapeutic areas and product classes, today announces that an abstract describing the background and methodology of its Phase I study, ACTIVATE, has been released for publication at the 2021 ASCO Annual Meeting.
The ACTIVATE Study (NCT04021277) is the first in a series of clinical investigations planned of the Company s Acoustic Cluster Therapy (ACT®) platform technology for targeted therapeutic enhancement.